<DOC>
	<DOCNO>NCT01011114</DOCNO>
	<brief_summary>The purpose study determine whether cinacalcet , use patient secondary hyperparathyroidism control excessive parathyroid hormone , normalize low blood phosphorus commonly see patient kidney transplant .</brief_summary>
	<brief_title>Using Cinacalcet Treat Hypophosphatemia Early Kidney Transplant</brief_title>
	<detailed_description>Secondary hyperparathyroidism ( SHPT ) , common ESRD , persist follow renal transplantation result profound hypophosphatemia . This lead hemolysis , congestive heart failure , rhabdomyolysis . Phosphate repletion difficult view persistent SHPT : oral phosphate supplementation lead hypocalcemia , reduce 1,25-OH Vitamin D production , hypercalcemia hyperparathyroidism . In addition , phospho-soda associate phosphate nephropathy renal failure . Cinacalcet HCl calcimimetic agent recently become standard therapy treatment SHPT ESRD . It suppress PTH secretion act modulator Calcium-sensing receptor PTH cell , cause PTH cell decrease production parathyroid hormone . It effective agent , produce significant reduction PTH well improvement calcium phosphate metabolism dialysis patient . The drug well-tolerated minimal adverse effect . Cinacalcet also use control hypercalcemia renal transplant patient persistent hyperparathyroidism . Short-term cinacalcet give 2 4 week normalize serum phosphorus decrease urinary phosphate waste renal transplant recipient stable graft function . We hypothesize Cinacalcet HCl normalize hypophosphatemia early renal transplant reduce effect PTH proximal renal tubular transport phosphorus , thereby allow phosphate reabsorption decrease urinary phosphate wasting .</detailed_description>
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>renal transplant within last 3 month serum phosphorus le 2.0 mg/dl serum creatinine le 2.0 mg/dl sensitivity cinacalcet use amitryptiline , desipramine , itraconazole , ketoconazole pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>hypophosphatemia</keyword>
	<keyword>hyperparathyroidism</keyword>
	<keyword>renal transplant</keyword>
</DOC>